Abstract: Disclosed herein is a method for identifying and treating an early-stage hepatocellular carcinoma (HCC) in a subject. The method mainly includes determining the level of serum amyloid A (SAA) protein, and providing anti-cancer treatment based on the determined level of SAA protein. According to some embodiments of the present disclosure, the anti-cancer treatment is provided when the determined level of SAA protein is lower than that of a first control sample, or when the determined level of SAA protein is higher than that of a second control sample. In some embodiments, the first control sample is derived from a subject having a late stage HCC, and the second control sample is derived from a subject having a liver disease that is any of hepatitis, liver cirrhosis, or a combination thereof.

Abstract: A biodegradable material with nanopores and the fabricating method thereof includes steps of providing a polysaccharide polymer; implanting multiple biodegradable nanoparticles on the polysaccharide polymer; and digesting those biodegradable nanoparticles through multiple enzymes to provide multiple nanopores on the polysaccharide polymer; the polysaccharide polymer being further implanted with a group of nano-grade electrically conductive material; and the biodegradable material with nanopores simultaneously providing advantages of biocompatibility, biodegradability, elasticity, retarded elasticity, porosity, and conductivity.